Pharma Generics

The rise and fall of Israeli industry leader Teva , reaching 69$ at the end of May 2015 only to fall off a cliff by August 2017,  and  settling  in a low range between $8 and $10 since three years, a story of extreme challenges buffeting the generics pharma industry

With aging populations in most developed countries, exploding healthcare costs and creaking insurance systems, and with better health coverage coming to the emerging markets, generics are strongly supported by national and local health authorities

But national as well as private health insurers press for more control over healthcare expenses. Increased competition, with more FDA approved generics brought on the US market every year, and sharper negotiations point towards commoditization and margin pressure

The October 2023 spin-off by Novartis , setting up Sandoz as alone-standing generics pharmaceutical firm, can be understood in this context